Inflammatory bowel diseases Fecal microbiota MALT Monitoring Algorithm Cancer Crohn’s disease Thérapie ciblée Patient-reported outcome Immunosuppressant Gene expression MORTALITY Vedolizumab Intestinal crypts Disability Biologics Colectomy Gènes Genes Microbiote Drug DNA methylation Résistance Cost effectiveness HIV Alkylating agents Primary sclerosing cholangitis Epigénétiques MARKER Inflammatory Bowel Diseases Bacteria IBD Inclusion Survival Ulcerative colitis Dysbiosis Rituximab plus chlorambucil Colon Anti-TNF Over 80s Disease progression IL12 Acceptability Heart disease risk factors Methylation MICROBIOTA Anti-TNF agents Neoadjuvant chemotherapy IL23 Inhibitor Gene methylation Disease Progression Maintenance therapy Rituximab Tuberculosis Resistance Parvimonas micra Endoscopic treatment Therapeutics Eligibility Safety Effectiveness Colorectal cancer Small molecules Crohn's disease DNA METHYLATION Original Article Clinical Clinical guidelines Venous thromboembolism Microbiota Kidney diseases CARCINOGENESIS Colorectal cancer Colibactin and lipids Consensus Clinical trial Colon cancer PCR Screening Méthylation COLON-CANCER Cell adhesion Stricture Inflammatory bowel disease RISK Surgery Biomarker Ustekinumab Upper gastrointestinal tract 18 FDG-PET/CT Tailored therapy Immune cells T1118 translocation Patients experience Bactéries Colonic epithelial primary cells Helicobacter pylori Eradication Epigenetics Dysbiose Contraindication